Results 51 to 60 of about 2,116 (170)

The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma

Frontiers in Pharmacology, 2019
Approximately 5–10% of asthmatic patients worldwide suffer from severe asthma. Experimental and clinical studies have demonstrated that IL-13 is an important cytokine in chronic airways inflammation.
Giancarlo Marone, Giancarlo Marone, Francescopaolo Granata, Francescopaolo Granata, Valentina Pucino, Antonio Pecoraro, Enrico Heffler, Enrico Heffler, Stefania Loffredo, Stefania Loffredo, Stefania Loffredo, Guy W. Scadding, Gilda Varricchi, Gilda Varricchi, Gilda Varricchi   +14 more
doaj   +1 more source

Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?

Dermatology and Therapy
Introduction Tralokinumab, a human IgG4 monoclonal antibody that inhibits the IL-13 pathway, is approved for the treatment of atopic dermatitis. However, real-world data are lacking and are needed to inform its efficacy and safety in broader populations.
Neenu Sebastian, Omar Chircop, Tim H. Clayton, Firas C. Kreeshan, Hamish J. A. Hunter, Richard B. Warren   +5 more
doaj   +1 more source

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

, 2019
© 2018 The Authors Background: IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13.
Christopher Kell, Andreas Wollenberg, Koustubh Ranade, Kell, Christopher, Wollenberg, Andreas, René van der Merwe, Silverberg, Jonathan I., Rachel Moate, Guttman-Yassky, Emma, Michael D. Howell, Moate, Rachel, Emma Guttman-Yassky, van der Merwe, René, Ranade, Koustubh, Jonathan I. Silverberg, Howell, Michael D.   +15 more
core   +1 more source

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Tralokinumab and dupilumab are biological agents licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates for systemic treatment.
Tiago Torres, Anne Sohrt Petersen, Ulla Ivens, Albert Bosch Vilaro, John Stinson, José Manuel Carrascosa   +5 more
doaj   +1 more source

Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma

BMC Pulmonary Medicine, 2019
Background Tralokinumab is an anti–interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2.
Mattis Gottlow, David J. Svensson, Ilya Lipkovich, Monika Huhn, Karin Bowen, Peter Wessman, Gene Colice   +6 more
doaj   +1 more source

Modern treatment methods in atopic dermatitis - literature overview

Journal of Education, Health and Sport
Introduction and aim: Atopic dermatitis (AD) is a chronic inflammatory skin disease. It is characterised by periods of exacerbation and remission of symptoms such as pruritus, dry skin and eczematous lesions with characteristic morphology.
Martyna Borowska-Łygan, Jakub Tomaszewski, Wojciech Urban, Konrad Strużek, Jan Biłogras, Kornelia Karamus, Rafał Wojciech Rejmak   +6 more
doaj   +1 more source

Dupilumab in patients with bullous pemphigoid and concomitant atopy

Frontiers in Pharmacology
BackgroundBullous pemphigoid (BP) and atopic dermatitis (AD) are chronic inflammatory skin diseases that may share overlapping immunopathogenic mechanisms, particularly a type 2 immune response.
Katerina Jobst, Stephan R. Künzel, Stephan R. Künzel, Stefan Beissert, Susanne Abraham   +4 more
doaj   +1 more source

Case Report: Differential response to IL-13 inhibition: lebrikizumab following primary tralokinumab failure in atopic dermatitis

Frontiers in Medicine
BackgroundAtopic dermatitis is a chronic inflammatory skin disorder driven largely by type 2 immune pathways, with interleukin-13 (IL-13) playing a central role in disease pathogenesis.
Shukry Abdi, Clare Bailey, Andreea Cifrea   +2 more
doaj   +1 more source

Over two years' experience with tralokinumab for moderate to-severe atopic dermatitis : three clinical case studies

, 2023
Tralokinumab is an anti-interleukin-13 monoclonal antibody approved in several geographical regions for the treatment of moderate-to-severe atopic dermatitis.
Halpern, James, Sarapuddin, Ben, Cuell, Alexis, Akbar, Faraz   +3 more
core  

Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory disease requiring long-term management. Biologic therapies have emerged as systemic treatment options for AD, and real-world evidence (RWE) of their use is needed to inform optimal treatment ...
Adrian O. Rodriguez, Caid Sterling Smith
doaj   +1 more source